Barriers to Effective Deliberation in Clinical Research Oversight

HEC Forum 28 (3):245-259 (2016)
  Copy   BIBTEX

Abstract

Ethical oversight of clinical research is one of the primary means of ensuring that human subjects are protected from the natural bias of researchers and research institutions in favor of experimentation. At a minimum, effective oversight should ensure that risks are minimized and reasonable in relation to anticipated benefits, protect vulnerable subjects from potential coercion or undue influence, ensure full and informed consent, and promote the equitable distribution of the risks and benefits of research. Because these assessments often involve value judgments for which there are no agreed-upon objective standards, we rely on deliberative procedures thought to have the greatest likelihood of producing the right or best outcomes. Concerns about the potential for improperly functioning IRBs to waste scarce human and institutional resources and impede biomedical progress have motivated a surge in empirical research assessing their procedures and outcomes. Yet within this literature, there has been minimal attention paid to the social scientific evidence regarding how individuals and deliberating groups make decisions, nor how those data might inform IRB practice. This essay seeks to fill that gap, locating recent empirical data on IRB composition and process within the context of data regarding what I call “deliberative pathologies,” or instances when deliberation fails to live up to one or more aspect of the deliberative ideal because of systematic biases in the ways participants interact. The paper goes on to make evidence-based recommendations to reduce the vulnerability of IRB deliberations to the kinds of pathologies discussed and indicate directions for future research.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,907

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

What we worry about when we worry about the ethics of clinical research.David Wendler - 2011 - Theoretical Medicine and Bioethics 32 (3):161-180.
Assessment of Barriers in Subject Recruitment for Clinical Trials.Ruckmani A. & Vishaly S. - 2012 - Journal of Clinical Research and Bioethics 3 (1).
Gene Therapy Oversight: Lessons for Nanobiotechnology.Susan M. Wolf, Rishi Gupta & Peter Kohlhepp - 2009 - Journal of Law, Medicine and Ethics 37 (4):659-684.
Financial conflicts and clinical research.Karin Meyers - 2009 - IRB: Ethics & Human Research 31 (4):17.
An Ethical Analysis of the Barriers to Effective Pain Management.Ben A. Rich - 2000 - Cambridge Quarterly of Healthcare Ethics 9 (1):54-70.
Scientific self-regulation—so good, how can it fail?Patrick L. Taylor - 2009 - Science and Engineering Ethics 15 (3):395-406.
Reflections on Governance Models for the Clinical Translation of Stem Cells.Jeremy Sugarman - 2010 - Journal of Law, Medicine and Ethics 38 (2):251-256.

Analytics

Added to PP
2015-12-01

Downloads
31 (#530,378)

6 months
9 (#352,597)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Danielle M. Wenner
Carnegie Mellon University